“Miramar Eye Specialist group continues its research study commitment with its involvement in the Artemis glaucoma study. Miramar physicians Joel Corwin MD, William Trotter MD, Wanda Hu MD, and Joseph Chen MD are enrolling patients in a study that will investigate a new method for glaucoma drug delivery. Bimatoprost SR is currently in phase 3 of FDA clinical trials and is the first major change in glaucoma drop delivery in over 10 years. This new method may potentially change the way we deliver care and increase medication effectiveness and patient compliance. To become a study patient, you will be asked a series of entry questions and will have to fulfill a number of study criteria. Once entered in the study, which is slated for one year with an additional year of follow-up, most costs of visits and medication are covered. We, the physicians at Miramar, are excited to advance glaucoma care and welcome your involvement.”
Submitted By Dr Trotter 02/10/2015
